If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
1S-LSD, also known as 1-(3-(trimethylsilyl)propionyl)-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the trimethylsilyl derivative of 1P-LSD and functions as a prodrug and functional analogue of LSD. 1S-LSD was developed in response to legal restrictions on similar compounds, such as 1D-LSD, which were banned in Germany under the NpSG law in June 2024. The compound was introduced as a legal alternative by incorporating a trimethylsilyl group, which is not covered under current NpSG regulations. This chemical modification allows 1S-LSD to be legally sold in Germany as of September 2024. It is typically distributed in its hemi-D-tartrate form, a common format for lysergamides due to its stability and ease of use.
According to Minister of the Interior Juan Carlos Bidegain, the law was meant to "guarantee the security, national sovereignty and social and political stability of the country". Although Bukele stated that the law was modeled on the United States' Foreign Agents Registration Act (FARA), critics have compared it to Nicaraguan laws that institute press censorship by shutting down organizations and arresting journalists. Human Rights Watch reported on 16 December 2021 that 91 Twitter accounts belonging to journalists, lawyers, and activists were blocked by Bukele and governmental institutions. In October 2024, when investigative journalists published a report that found that Bukele, his three brothers, wife, and mother had purchased 34 properties valued at US$9 million during Bukele's first presidential term, Bukele referred to the journalists as "imbeciles" and denied accusations of corruption.
== Impact and aftermath == Syrian rebels took advantage of the war, the heavy losses suffered by Hezbollah, and Hezbollah's absence in Syria to launch the 2024 Syrian opposition offensive on 27 November 2024 to overrun Syria's government-held territories. Hezbollah, which had previously sent forces, said they would not deploy troops, but later sent "supervising forces" to unsuccessfully attempt to repel the 2024 Homs offensive, as Homs is a key transport route for Iran to supply Hezbollah. In December 2024, the fall of Assad's Baathist regime in Syria was another blow to its Lebanese ally, Hezbollah, which was already weakened because of Israeli military actions. Following major operations in 2024, numerous analysts and experts have characterized the outcome as a significant victory for Israel. The Institute for the Study of War reported that Israeli operations effectively degraded Hezbollah's capabilities, leading to a ceasefire agreement on November 26, 2024, which mandated Hezbollah's disarmament in southern Lebanon. Hezbollah failed to accomplish its goal of compelling Israel to cease operations in the Gaza Strip, resulting in a weakened position within the region. Similarly, experts from the Atlantic Council noted that Israel's military actions, including the elimination of Hezbollah's leader, Hassan Nasrallah, significantly diminished the group's operational effectiveness.
== Prevention == A future way to reduce waste accumulation is to phase out current reactors in favor of Generation IV reactors, which output less waste per power generated. Fast reactors such as BN-800 in Russia are also able to consume MOX fuel that is manufactured from recycled spent fuel from traditional reactors. The UK's Nuclear Decommissioning Authority published a position paper in 2014 on the progress on approaches to the management of separated plutonium, which summarises the conclusions of the work that the NDA shared with the UK government.
Sources: en.wikipedia.org
In the absence of other glucogenic sources, the 2-carbon acetyl-CoA derived from the oxidation of fatty acids cannot produce a net yield of glucose via the citric acid cycle, since an equivalent two carbon atoms are released as carbon dioxide during the cycle. During ketosis, however, acetyl-CoA from fatty acids yields ketone bodies, including acetone, and up to ~60% of acetone may be oxidized in the liver to the pyruvate precursors acetol and methylglyoxal. Thus ketone bodies derived from fatty acids could account for up to 11% of gluconeogenesis during starvation. Catabolism of fatty acids also produces energy in the form of ATP that is necessary for the gluconeogenesis pathway.
=== Research === Many aspects of academic research and industrial research such as in pharmaceuticals, health products, and many others relies on accurate water analysis to identify substances of potential use, to refine those substances and to ensure that when they are manufactured for sale that the chemical composition remains consistent. The analytical methods used in this area can be very complex and may be specific to the process or area of research being conducted and may involve the use of bespoke analytical equipment.
==== Australia and New Zealand ==== Australia and New Zealand published nutrient reference values including guidelines for dietary vitamin D intake in 2006. About a third of Australians have vitamin D deficiency.
Sources: en.wikipedia.org
Amino acids are organic compounds that contain both amino and carboxylic acid functional groups. Although over 500 amino acids exist in nature, by far the most important are the 22 α-amino acids incorporated into proteins. Only these 22 appear in the genetic code of life. Amino acids can be classified according to the locations of the core structural functional groups (alpha- (α-), beta- (β-), gamma- (γ-) amino acids, etc.); other categories relate to polarity, ionization, and side-chain group type (aliphatic, acyclic, aromatic, polar, etc.). In the form of proteins, amino-acid residues form the second-largest component (water being the largest) of human muscles and other tissues. Beyond their role as residues in proteins, amino acids participate in a number of processes such as neurotransmitter transport and biosynthesis. It is thought that they played a key role in enabling life on Earth and its emergence. Amino acids are formally named by the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature in terms of the fictitious "neutral" structure shown in the illustration. For example, the systematic name of alanine is 2-aminopropanoic acid, based on the formula CH3−CH(NH2)−COOH. The Commission justified this approach as follows:
By that time, BMS had already withdrawn the drug from the market in Europe, Australia, New Zealand, and Canada. In August 2020, Teva Pharmaceuticals placed nefazodone in shortage due to a shortage of a raw ingredient. On December 20, 2021, nefazodone was again made available in all strengths.
US and Canada: Pentacarinat 300 injection powder 300 mg vial (Avantis Pharma Inc - Canada) Pentam 300 (APP Pharmaceuticals LLC - US) Pentamidine isethionate 300 mg for injection (David Bull Laboratories LTD - Canada, Hospira Healthcare Corporation - Canada) International Brands: Pentamidine isethionate (Abbott) Pentacarinat (Sanofi-Aventis) Pentacrinat (Abbott) Pentam (Abbott) Pneumopent
(…)John Fisher says, based on a detailed study of the Liberator's correspondence: "To a certain extent his decision to go personally to Peru in August 1823 meant the desire to protect Gran Colombia from the Peruvians." Given this, he would try to wrest territories from him. to the Peruvians in the north, taking advantage of the fact that the independence Peru was still in the process of establishing itself as a sovereign country, despite being aware that provinces such as Maynas or Guayaquil were legally and culturally closer to Peru than to Colombia according to the principle of Uti possidetis iuris that he defended, which would be evidence of total dishonesty on his part to impose the expansionist interests of Gran Colombia against the Peruvians. "Have you understood that the Corregimiento de Jaén has been occupied by those from Peru; and that Maynas belongs to Peru by a very modern Royal Order [Royal Cedula of 1802]: that it is also occupied by forces from Peru.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.